Systagenix at Gargrave

History of Gargrave Facility

• 1780     Original woollen mill built

• 1924     Johnson & Johnson Limited established in the U.K.

• 1934     Gargrave site acquired by Johnson & Johnson

• 1960     Research & Development presence established

• 1973    Major facility extension

• 1992     Cobalt sterilisation unit commissioned

• 1995     Gargrave designated European Operations Centre

• 1997    Specialist biopolymers R&D group relocate to Gargrave

• 2003     U.S. A.W.C. & Biocides relocated to Gargrave

• 2004     Freeze Drying facility is validated

• 2007     New Technology Centre opens

• 2008     Johnson & Johnson divest Professional Wound Care business and

• Systagenix Wound Management established

• 2009    Celebrating 75 years of Medical Device Manufacture

Total amount of major investments 2003 – 2009: $23.44MM

Gargrave Facility Workforce

• Providing a broad range of skilled jobs in a rural economy

  • Manufacturing: 175

  • Engineering/Technology: 44

  • R&D, Regulatory & support functions: 112

  • Agency staff: 51

  • Total: 382

50 people with 25 years’ service & over

• Supporting the local community

  • Community Action Group events

  • Supporting local charities

  • Supporting local schools and hospitals

• Driving higher standard of care in the UK

  • One of the most penetrated markets in wound care

  • Gargrave continues to play a significant role

• Sustaining UK’s strength in innovation

• • Centre of Excellence for Wound Healing

19 Nov 2010